Here is a detailed review of the most material insider trading activity reported on Thursday across U.S. public markets. The filings cover purchases and dispositions by company directors, executives and affiliated investment entities, with transaction sizes ranging from the tens of thousands of dollars to more than a hundred million dollars in proceeds.
Top insider purchases
Prelude Therapeutics Inc. (NASDAQ:PRLD) registered the largest insider buy disclosed on Thursday. David P. Bonita - identified as a director and a 10% owner - acquired a block of common stock valued at roughly $12.5 million on April 21, 2026. The filing shows purchases of 2,815,315 shares at $4.44 per share, a price reported just above the prevailing market quote of $4.41 at the time of the disclosure.
The transactions were executed as part of an underwritten public offering and were structured to include common stock held indirectly by affiliated entities. Of the total shares, 1,689,189 are recorded as held by OrbiMed Private Investments VI, LP, while the remaining 1,126,126 shares are held of record by OrbiMed Genesis Master Fund, L.P. The filing indicates the purchases were made in connection with the offering - rather than as isolated open-market buys - and were reported on the requisite SEC filings.
Prelude shares have been on a strong run, according to the filing details: the stock has returned roughly 398% over the last 12 months and climbed 193% during the past six months, while the company has recorded revenue growth of 73% in the period referenced in the filing.
Alongside Mr. Bonita’s filing, OrbiMed Advisors LLC and related OrbiMed affiliates - including OrbiMed Capital GP VI LLC, ORBIMED CAPITAL LLC and OrbiMed Genesis GP LLC - disclosed the same acquisition. The combined OrbiMed purchases summed to 2,815,315 shares at $4.44 apiece, representing approximately $12,499,998 of additional stake acquired in the offering on April 21, 2026.
Bank First Corp (NASDAQ:BFC) saw two directors report purchases this week. Todd A. Sprang purchased 450 shares on April 22, 2026, at $138.96 per share for a total consideration of $62,532. Following that purchase, Mr. Sprang’s direct holdings in Bank First common stock stand at 2,015 shares. The stock has since been reported trading at $141.83 and has delivered a 31% return over the past year. The filing also notes the bank’s reported market size of approximately $1.58 billion and a price-to-earnings ratio of 19.68, with the company maintaining dividend payments for 17 consecutive years and a current yield of 1.58%.
Separately, director Michael S. Stayer-Suprick reported a purchase of 225 shares on April 21, 2026, at $140.04 per share. That transaction totaled $31,509 and brings his direct ownership to 4,597 shares. The Form 4 reporting for Mr. Stayer-Suprick was filed with the SEC on April 23, 2026.
Travel & Leisure Co. (TNL) recorded an insider buy from the company’s chief financial officer, Erik D. Hoag, who acquired 1,000 shares on April 23, 2026. The shares were purchased at $65.67 each for a total value of $65,670. After the purchase Mr. Hoag directly holds 1,000 shares of Travel & Leisure Co. common stock and, in addition, holds 110,336 previously reported restricted stock units.
Top insider sales
NuScale Power Corp (NASDAQ:SMR) reported the single-largest insider sale by dollar amount among the filings. Fluor Corp, which is listed as a director-level stakeholder for NuScale, disposed of 13,500,000 shares on April 21, 2026. The shares were sold at $11.8092 apiece, producing proceeds of approximately $159,424,200. The filing states the sale was executed pursuant to a previously disclosed agreement. At the time of the disclosure the stock has since been noted trading at $13.57, and the filing highlights that NuScale remains down about 64% over the last six months.
CoreWeave, Inc. (CRWV) CEO and president Michael N. Intrator reported dispositions totaling roughly $35.8 million on April 21, 2026. The filing details the sale of 297,693 shares of Class A common stock with prices ranging from $114.709 to $120.328 per share. The sales were carried out both directly by Mr. Intrator - accounting for 190,000 shares - and indirectly through Omnadora Capital LLC - accounting for 107,693 shares. The disclosure notes that these transactions were undertaken pursuant to a Rule 10b5-1 trading plan Mr. Intrator adopted on November 20, 2025. Post-sale holdings show Mr. Intrator directly holds 5,066,501 shares of Class A common stock, while Omnadora Capital LLC’s balance in the security stands at zero. The filing also records CoreWeave shares have gained roughly 181% over the past year, with the stock trading at $117.42 at the time of reporting.
Arista Networks, Inc. (NASDAQ:ANET) reported a multi-transaction sale by CEO and chairperson Jayshree Ullal. The filings list the indirect sale of 93,861 shares through various trusts on April 21, 2026, at prices ranging from $167.6403 to $170.5066 per share, producing proceeds of about $15.8 million. The filing specifies these trades were executed under Rule 10b5-1 trading plans established on November 14, 2025. Arista stock was reported trading near its 52-week high of $178.48, with a one-year return of approximately 144% at the time of disclosure.
Everpure, Inc. (NASDAQ:P) listed a series of sales attributed to Chief Visionary Officer John Colgrove between April 21 and April 23, 2026. The filings show Class A common stock dispositions totaling $12,021,056, with share prices ranging from $70.04 to $71.08. The transactions were executed under a Rule 10b5-1 plan Mr. Colgrove adopted on January 8, 2026, and involved shares held by multiple trusts: The RWC Irrevocable Trust, The EEC Irrevocable Trust, and VCF Trust. Despite the recent sales, the filing indicates Mr. Colgrove retains a meaningful position both directly and indirectly through trusts. Everpure shares were recorded trading at $69.98, down 25% over the past six months but up nearly 64% over the trailing year.
SBC Medical Group Holdings Inc. (NASDAQ:SBC) disclosed a substantial disposition by chairman and CEO Aikawa Yoshiyuki. The filing shows Mr. Aikawa sold 3,100,000 shares on April 21, 2026, as part of an underwritten public offering that closed the same day. The offering price was $3.0225 per share for total proceeds of $9,369,750. Following the direct sale, Mr. Aikawa’s reported direct holdings total 79,304,460 shares. The filing notes SBC shares were trading at $3.40, slightly above the offering price, and that the stock had declined about 24% over the prior week.
What the filings show and what they do not
The disclosures cover a spectrum of transaction types: purchases within an underwritten offering, open-market acquisitions, and sales executed under pre-existing Rule 10b5-1 plans. Several filings explicitly identify the instruments used - common stock and Class A common stock - and whether holdings are direct or held of record by affiliated entities or trusts. The filings also report contemporaneous market quotes, multi-period returns and, in some cases, company-level metrics such as revenue growth and dividend history.
It is important to note that the filings provide facts about executed transactions, prices and holdings, but they do not provide definitive explanations for insider decisions. While purchases can be interpreted by some market participants as a sign of confidence and sales by insiders as a potential signal, the disclosures themselves do not attribute personal motives. For example, several sales were executed under Rule 10b5-1 plans or pursuant to previously disclosed agreements, mechanisms that are commonly used to pre-schedule or contractually manage dispositions for tax, diversification or liquidity needs.
Implications for market sectors
The reported activity touches multiple sectors: biotechnology and life sciences via Prelude Therapeutics; regional banking through Bank First Corp; leisure and hospitality with Travel & Leisure Co.; clean energy and nuclear via NuScale Power; cloud infrastructure at CoreWeave; networking hardware in Arista Networks; consumer-oriented or industrial filtration services at Everpure; and medical supplies and services through SBC Medical Group. These filings provide discrete, company-level signals that investors and analysts can incorporate into broader sector views, while recognizing the limitations of inferring intent solely from transaction records.
Monitoring insider filings remains a routine part of company analysis. The filings disclosed on Thursday provide a mix of large purchases, strategic institution-led entries through an offering, and notable sales executed under established plans and agreements. Each filing contributes to the public record of insider holdings and provides context for investors conducting due diligence.